RIZZARI CARMELO

Moricke, A., Rizzari, C., Alten, J., Attarbaschi, A., Beier, R., Biondi, A., et al. (2023). Hypersensitivity Reactions to Native E. coli L-asparaginase in Children with Acute Lymphoblastic Leukemia Treated in Trial ALL-BFM 2000: Impact of Treatment Schedule and Type of Glucocorticoid in Induction. HEMASPHERE, 7(6), 888-890 [10.1097/HS9.0000000000000888]. Detail

Rizzari, C., Möricke, A., Valsecchi, M., Conter, V., Zimmermann, M., Silvestri, D., et al. (2023). Incidence and Characteristics of Hypersensitivity Reactions to PEG-asparaginase Observed in 6136 Children with Acute Lymphoblastic Leukemia Enrolled in the AIEOP-BFM ALL 2009 Study Protocol. HEMASPHERE, 7(6), 893-895 [10.1097/HS9.0000000000000893]. Detail

Locatelli, F., Zugmaier, G., Rizzari, C., Morris, J., Gruhn, B., Klingebiel, T., et al. (2023). Improved survival and MRD remission with blinatumomab vs. chemotherapy in children with first high-risk relapse B-ALL. LEUKEMIA, 37(1), 222-225 [10.1038/s41375-022-01770-3]. Detail

Brivio, E., Cossio, A., Borra, D., Silvestri, D., Prunotto, G., Colombini, A., et al. (2022). Osteonecrosis in paediatric acute lymphoblastic leukaemia: Incidence, risk factors, radiological patterns and evolution in a single-centre cohort. BRITISH JOURNAL OF HAEMATOLOGY, 197(5), 602-608 [10.1111/bjh.18147]. Detail

Fazio, G., Bresolin, S., Silvestri, D., Quadri, M., Saitta, C., Vendramini, E., et al. (2022). PAX5 fusion genes are frequent in poor risk childhood acute lymphoblastic leukaemia and can be targeted with BIBF1120. EBIOMEDICINE, 83(September 2022) [10.1016/j.ebiom.2022.104224]. Detail